Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00137332 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating GAP-486 on Heart Rhythm in Patients With Coronary Artery Disease
A Phase 2 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
NCT00137332 is a Phase 2 study that was terminated before completion, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 90 participants.
The verdict
NCT00137332, a Phase 2 study, was terminated before completion, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
Study Summary
The purpose of this study is to learn the effects of a test drug on heart rhythms, which may become life-threatening if left untreated, and to provide data to see if the drug is well tolerated and safe.
Interventions
- DRUG GAP-486 (ZP-123)
- DRUG 0.9% Sodium Chloride, USP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2005-11 |
| Est. Completion | 2006-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00137332
The ClinicalTrials.gov registry entry for NCT00137332 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which GAP-486 (ZP-123) is the first listed.
NCT00137332 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00137332 about?
NCT00137332 is a clinical study titled "Study Evaluating GAP-486 on Heart Rhythm in Patients With Coronary Artery Disease". The purpose of this study is to learn the effects of a test drug on heart rhythms, which may become life-threatening if left untreated, and to provide data to see if the drug is well tolerated and safe.
What is the current status of trial NCT00137332?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2005-11. Estimated completion is 2006-10.
What interventions are being tested in trial NCT00137332?
The interventions under investigation include: GAP-486 (ZP-123) (DRUG), 0.9% Sodium Chloride, USP (DRUG).
Who is sponsoring clinical trial NCT00137332?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.